Anthony D. Kolton:
President and CEO
Anthony Kolton is President and the business Founder of RMS. Mr. Kolton has had extensive experience and a successful track record in both start-ups and technology companies. He founded Logical Information Machines (LIM) in 1988 with three other partners, each putting up $1,000 in capital for a total $4,000 in capital and, under his direction as President, turned the company into a business with revenues over $20 million per year. He also invented the “Market Information Machine”, a tool that allows you to ask any question about any market and obtain an instant answer, which was the flagship product of LIM. In December 2009, LIM was sold to Morningstar for over $50 million.
Mr. Kolton earned a Bachelor of Science degree in Accounting from DePaul University and subsequently his CPA certificate. He also earned both a Masters in Taxation degree and a Juris Doctor degree in law from DePaul University, after attending both programs simultaneously at night.
Dr. Jon Odorico is the Chief Scientific Officer and the Scientific Founder of RMS. He is responsible for the overall scientific direction of the Company. Dr. Odorico is also a Professor, Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison School of Medicine and Public Health in Madison, WI. Dr. Odorico is certified by the American Board of Surgery and specializes in pancreas transplants, islet cell transplants and multi-organ transplants. In addition, he performs general surgery procedures on transplant patients. He currently serves as Director of both the Pancreas and Islet Transplantation Programs. He received his B.S. degree in the field of chemistry from Duke University in 1983 and his medical degree from New York University, School of Medicine in 1987. He then completed training in General Surgery and Transplantation at the University of Pennsylvania and the University of Wisconsin, respectively.
Jon S. Odorico, MD, FACS
He has received numerous awards in his research field of study, including the National Research Service Award from the National Institutes of Health, the Jonathon E. Rhoads Research Award from the Harrison Department of Surgical Research, at University of Pennsylvania School of Medicine, the Best Abstract Award from OrthoBiotech Transplant Fellows Workshop, Howard Hughes Medical Institute Faculty Development Award, the Vilas Associate Award from the University of Wisconsin and the Fujisawa Faculty Development Award from American Society of Transplant Surgeons. He has worked in the field of stem cell research and diabetes for over 15 years and is a key thought leader in the field as evidenced by numerous peer-reviewed publications and book chapters, as well as service on grant review boards. Dr. Odorico co-authored the textbook, Human Embryonic Stem Cells ©2005, Taylor and Francis, ISBN: 1859962785. Over the years he has worked with Dr. James Thomson, the University of Wisconsin stem cell pioneer, collaborating with him on grants and publications. Dr. Odorico is also a member of the Stem Cell and Regenerative Medicine Center at the University of Wisconsin and regularly collaborates with many stem cell scientists worldwide.
As Chief Scientific Officer at Regenerative Medical Solutions, Dr. Ramamoorthy leads pre-clinical, translational research and clinical development of our islet like cluster (ILC) cellular therapeutic for Diabetes. He has 18 years of combined biologics development, precision medicine diagnostics, therapeutic medical device and cell & gene therapy industry experience. At MedImmune (an Astra Zeneca company), he was part of a team that developed viral vaccines, monoclonal antibody therapeutics and gene therapies including two commercialized products- FluMist® and Synagis®. Dr. Ramamoorthy founded National Jewish Health’s first precision medicine diagnostics laboratory and commercialized 22 molecular and clinical genomic tests.
Dr. Preveen Ramamoorthy
Chief Scientific Officer
As Assistant Professor at the Department of Medicine at National Jewish Health (Denver, CO), he pioneered a translational research program to discover and validate genomic biomarkers for immune, lung and infectious diseases resulting in numerous grants, publications and diagnostic tests. As global head of diagnostics at Strand Life Sciences (Bangalore, India), Dr. Ramamoorthy played a transformative role in evolving this internationally renowned bioinformatics and life sciences company into a precision medicine company. At Strand he led the successful international CAP accreditation for India’s first clinical genomic facility. Dr. Ramamoorthy co-led the affordable innovation initiative leading to greater Indian patient access to clinical genomic diagnostics. In addition, he built from ground up Strand’s US reference laboratory and commercialized a 152 gene solid tumor cancer precision medicine test (StrandAdvantage) for the US oncology market. At TerumoBCT one of the world’s leading therapeutic medical device companies focused on transfusion medicine and cell & gene therapy, Dr. Ramamoorthy was the global R&D head and VP for all pre-clinical, translational research and clinical development. He led the expansion of TerumoBCT’s global R&D footprint for cell & gene therapy programs and led scientific collaborations for CAR T and MSC cell therapy development with numerous biopharma companies. Dr. Ramamoorthy launched two global clinical trials in hematopoietic stem cell transplantation and therapeutic plasmapheresis in addition to leading numerous other clinical trials for global regulatory approvals in the US, EU, Japan, India and China. Most recently, he was the VP and head of R&D for HealthTell (an iCarbonX company) where he led the technology and applications development of massively parallel protein and antibody profiling platforms. In addition, he led multi-omic clinical biomarker trials of rare disease and immune disease patient cohorts. Dr. Ramamoorthy serves as adjunct faculty at the department of medicine, University of Colorado school of medicine and serves on non-profit boards related to rare diseases, immune diseases and autism.
Gary J. Gorman
Gary Gorman is a founding partner of RMS. Mr. Gorman is President and CEO of Gorman & Company. The company currently employs more than 120 people, producing 300 new apartments per year through its in-house general contracting division. As President and CEO, Gary has broad responsibility for all operations of the company. Gary Gorman received an Economics degree from the University of Wisconsin in 1977 and graduated from the UW Law School in 1980. He practiced real estate and securities law at a Madison-based firm for four years before founding Gorman & Company in 1984.
Tom Joyce is Vice President of Corporate Development and Administration of Regenerative Medical Solutions. In this role he manages day-to-day operations of finance, marketing and logistics for RMS. He previously was a key market researcher with Logical Information Machines specializing in developing data, conducting research and streamlining financial operations. Mr. Joyce was named to the Dean’s List in all semesters and graduated Summa Cum Laude with a degree in Finance and Banking from the Trulaske College of Business at the University of Missouri-Columbia.
Thomas P. Joyce: